In Australia prostate cancer is the most prevalent non skin cancer in men with 1 in 7 men diagnosed with prostate cancer by the age of 75 years. (1)  PSA screening has led to a stage shift into a lower volume prostate cancer with a marked decline in the presentation of high volume or metastatic prostate cancer upon diagnosis. This has been associated with a decline in prostate cancer death (2).  PSA has also led to an increased risk of diagnosis of a low volume, potentially clinically insignificant prostate malignancy. Current options for management of localised prostate cancer in Australia … Continue reading Current treatment options for localised prostate cancer